Novo Nordisk CEO talks GLP-1 pill at JPMorgan conference
CNBC • • business
Key Points:
- The 2026 outlook for the biotech and pharma sector is optimistic, with major drug pricing and tariff challenges largely resolved, falling interest rates, and promising scientific advancements driving positive sentiment at the JPMorgan Healthcare Conference.
- Novo Nordisk plans to expand the incretin market with its new oral and injectable Wegovy obesity drugs, but anticipates significant price pressure in 2026 due to pricing deals and generic competition, aiming to offset this with volume growth and potential pipeline-enhancing acquisitions.
- Bristol Myers Squibb expects to launch up to 10 new products by 2030, focusing on a diverse late-stage pipeline including Alzheimer's psychosis treatments, while actively seeking innovative science through broad business development efforts.
- Pfizer is committed to obesity treatments following its $
